End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria.
Recent trials in glioma have revealed significant limitations in the end points used. This requires a critical and comprehensive review of how brain tumor trials are conducted, particularly of which end points are defined and how response and progression are defined.
van den Bent
Martin J
MJ
Neuro-Oncology Unit, Daniel den Hoed Cancer Center, Erasmus University Hospital, Rotterdam, The Netherlands.
Vogelbaum
Michael A
MA
Wen
Patrick Y
PY
Macdonald
David R
DR
Chang
Susan M
SM
D001932:Brain Neoplasms / Q000628:therapy*; D018450:Disease Progression; D005910:Glioma / Q000628:therapy*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012107:Research Design